FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4239155092> ?p ?o ?g. }

• W4239155092 abstract "Background During percutaneous coronary intervention (PCI), and in non‐ST segment elevation acute coronary syndromes (NSTEACS), the risk of acute vessel occlusion by thrombosis is high. Glycoprotein IIb/IIIa blockers strongly inhibit platelet aggregation and may prevent mortality and myocardial infarction. This is an update of a Cochrane review first published in 2001, and previously updated in 2007 and 2010. Objectives To assess the efficacy and safety effects of glycoprotein IIb/IIIa blockers when administered during PCI, and as initial medical treatment in patients with NSTEACS. Search methods We updated the searches of the Cochrane Central Register of Controlled Trials (CENTRAL) on The Cochrane Library (Issue 12, 2012), MEDLINE (OVID, 1946 to January Week 1 2013) and EMBASE (OVID, 1947 to Week 1 2013) on 11 January 2013. Selection criteria Randomised controlled trials comparing intravenous IIb/IIIa blockers with placebo or usual care. Data collection and analysis Two authors independently selected studies for inclusion, assessed trial quality and extracted data. We collected major bleeding as adverse effect information from the trials. We used odds ratios (OR) and 95% confidence intervals (CI) for effect measures. Main results Sixty trials involving 66,689 patients were included. During PCI (48 trials with 33,513 participants) glycoprotein IIb/IIIa blockers decreased all‐cause mortality at 30 days (OR 0.79, 95% CI 0.64 to 0.97) but not at six months (OR 0.90, 95% CI 0.77 to 1.05). All‐cause death or myocardial infarction was decreased both at 30 days (OR 0.66, 95% CI 0.60 to 0.72) and at six months (OR 0.75, 95% CI 0.64 to 0.86), although severe bleeding was increased (OR 1.39, 95% CI 1.21 to 1.61; absolute risk increase (ARI) 8.0 per 1000). The efficacy results were homogeneous for every endpoint according to the clinical condition of the patients, but were less marked for patients pre‐treated with clopidogrel, especially in patients without acute coronary syndromes. As initial medical treatment of NSTEACS (12 trials with 33,176 participants), IIb/IIIa blockers did not decrease mortality at 30 days (OR 0.90, 95% CI 0.79 to 1.02) or at six months (OR 1.00, 95% CI 0.87 to 1.15), but slightly decreased death or myocardial infarction at 30 days (OR 0.91, 95% CI 0.85 to 0.98) and at six months (OR 0.88, 95% CI 0.81 to 0.96), although severe bleeding was increased (OR 1.29, 95% CI 1.14 to 1.45; ARI 1.4 per 1000). Authors' conclusions When administered during PCI, intravenous glycoprotein IIb/IIIa blockers reduce the risk of all‐cause death at 30 days but not at six months, and reduce the risk of death or myocardial infarction at 30 days and at six months, at a price of an increase in the risk of severe bleeding. The efficacy effects are homogeneous but are less marked in patients pre‐treated with clopidogrel where they seem to be effective only in patients with acute coronary syndromes. When administered as initial medical treatment in patients with NSTEACS, these agents do not reduce mortality although they slightly reduce the risk of death or myocardial infarction." @default.
• W4239155092 created "2022-05-12" @default.
• W4239155092 creator A5082431864 @default.
• W4239155092 creator A5087128549 @default.
• W4239155092 creator A5090498143 @default.
• W4239155092 date "2013-10-18" @default.
• W4239155092 modified "2023-10-13" @default.
• W4239155092 title "Platelet glycoprotein IIb/IIIa blockers during percutaneous coronary intervention and as the initial medical treatment of non-ST segment elevation acute coronary syndromes" @default.
• W4239155092 cites W140627064 @default.
• W4239155092 cites W1489918304 @default.
• W4239155092 cites W1553345686 @default.
• W4239155092 cites W1602674819 @default.
• W4239155092 cites W162059335 @default.
• W4239155092 cites W1676021479 @default.
• W4239155092 cites W183456607 @default.
• W4239155092 cites W184119209 @default.
• W4239155092 cites W1965911938 @default.
• W4239155092 cites W1966105966 @default.
• W4239155092 cites W1967264661 @default.
• W4239155092 cites W1971010543 @default.
• W4239155092 cites W1972109636 @default.
• W4239155092 cites W1979083612 @default.
• W4239155092 cites W1982365463 @default.
• W4239155092 cites W1982767778 @default.
• W4239155092 cites W1984101066 @default.
• W4239155092 cites W1984228274 @default.
• W4239155092 cites W1984258208 @default.
• W4239155092 cites W1984328874 @default.
• W4239155092 cites W1984441154 @default.
• W4239155092 cites W1985684249 @default.
• W4239155092 cites W1988171809 @default.
• W4239155092 cites W1992850917 @default.
• W4239155092 cites W1993578099 @default.
• W4239155092 cites W1996538398 @default.
• W4239155092 cites W1996669893 @default.
• W4239155092 cites W1998771467 @default.
• W4239155092 cites W2000205702 @default.
• W4239155092 cites W2001082646 @default.
• W4239155092 cites W2004897549 @default.
• W4239155092 cites W2006108796 @default.
• W4239155092 cites W2007516629 @default.
• W4239155092 cites W2011657702 @default.
• W4239155092 cites W2012618710 @default.
• W4239155092 cites W2014080052 @default.
• W4239155092 cites W2014390331 @default.
• W4239155092 cites W2015182475 @default.
• W4239155092 cites W2015367522 @default.
• W4239155092 cites W2016562783 @default.
• W4239155092 cites W2017207038 @default.
• W4239155092 cites W2017842679 @default.
• W4239155092 cites W2020759112 @default.
• W4239155092 cites W2020820110 @default.
• W4239155092 cites W2020951163 @default.
• W4239155092 cites W2023133108 @default.
• W4239155092 cites W2024352468 @default.
• W4239155092 cites W2025510606 @default.
• W4239155092 cites W2027265158 @default.
• W4239155092 cites W2028470404 @default.
• W4239155092 cites W2031944010 @default.
• W4239155092 cites W2033969199 @default.
• W4239155092 cites W2035015235 @default.
• W4239155092 cites W2037545303 @default.
• W4239155092 cites W2038403325 @default.
• W4239155092 cites W2039220869 @default.
• W4239155092 cites W2041039863 @default.
• W4239155092 cites W2042318890 @default.
• W4239155092 cites W2042916363 @default.
• W4239155092 cites W2044790100 @default.
• W4239155092 cites W2048562616 @default.
• W4239155092 cites W2048615527 @default.
• W4239155092 cites W2052694025 @default.
• W4239155092 cites W2054075375 @default.
• W4239155092 cites W2054240662 @default.
• W4239155092 cites W2055474976 @default.
• W4239155092 cites W2058378731 @default.
• W4239155092 cites W2059136191 @default.
• W4239155092 cites W2059215195 @default.
• W4239155092 cites W2059312457 @default.
• W4239155092 cites W2059332570 @default.
• W4239155092 cites W2061840838 @default.
• W4239155092 cites W2064093913 @default.
• W4239155092 cites W2064739148 @default.
• W4239155092 cites W2065150922 @default.
• W4239155092 cites W2065364210 @default.
• W4239155092 cites W2066886523 @default.
• W4239155092 cites W2068916210 @default.
• W4239155092 cites W2073159589 @default.
• W4239155092 cites W2073751205 @default.
• W4239155092 cites W2075184170 @default.
• W4239155092 cites W2078584308 @default.
• W4239155092 cites W2078717753 @default.
• W4239155092 cites W2082306741 @default.
• W4239155092 cites W2083483216 @default.
• W4239155092 cites W2084673482 @default.
• W4239155092 cites W2085854247 @default.
• W4239155092 cites W2087690114 @default.
• W4239155092 cites W2091054752 @default.
• W4239155092 cites W2094687142 @default.
• W4239155092 cites W2095901832 @default.
• W4239155092 cites W2099058771 @default.

• next